Metsera’s Amylin Drug Looks Good in Phase 1, Shows Potential to Be a Once-Monthly Obesity Med

Metsera’s Amylin Drug Looks Good in Phase 1, Shows Potential to be a Once-Monthly Obesity Med

Novo Nordisk, AbbVie, and Roche each have weekly injectable drug candidates designed to bind to and activate the amylin receptor to trigger weight loss. Metsera’s contender, MET-233i, is designed with technology that enables longer dosing intervals and the company is proceeding with development of this engineered peptide as a monotherapy and as part of a drug combination. The post Metsera’s Amylin Drug Looks Good in Phase 1, Shows Potential to b…

Metsera’s drug shows potential in early clinical trial

Today's biotech news includes Metsera’s amylin drug showing early potential, FDA aims to "be flexible" on gene therapy regulation, and more.

Metsera shares climb on early data for amylin-targeting obesity shot

Early-stage study results suggest that a single shot of the company’s therapy, which works differently than GLP-1 medicines, might have effects that last at least four weeks.

Metsera shares early data on anti-obesity amylin candidate

Metsera, which is attempting to make long-acting obesity and metabolic disease medicines, has shared its first clinical data as a recently minted public company. The New York-based biotech said Monday morning that its amylin analog ...